Oral Victoza: Is There a Pill Version of Liraglutide?

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Part of the PlexusDx Education Hub, where we translate GLP-1 science, metabolic biology, and the genetics behind weight regulation into plain language. Browse the full Peptides & GLP-1 library.

Victoza is one of the older names in the GLP-1 world, which is exactly why people ask whether it comes as a pill. This page reports what format Victoza actually uses, why an oral version is not part of the picture, and how its once-daily rhythm compares with the weekly injections that now dominate the conversation.

Victoza is a once-daily injection

Victoza is the liraglutide brand, and its authorized format is the format printed on its FDA-approved label. For any specific product, the reliable move is to check the prescribing information or ask a licensed provider which formats are currently authorized rather than assuming a pill exists. Liraglutide is notable in this class for its once-daily injection schedule.

Why no Victoza pill is on the shelf

Like every GLP-1 receptor agonist, liraglutide is a peptide, and peptides are dismantled by stomach acid and digestive enzymes. Injection sidesteps that problem and delivers predictable bioavailability. The only widely known oral workaround in this class is Rybelsus, an oral semaglutide that relies on a SNAC absorption enhancer and strict fasting administration, an approach that has not produced an oral Victoza.

Daily versus weekly GLP-1 dosing

Dosing rhythm varies across the class. Injectable liraglutide is dosed once daily, while most newer injectable agonists are weekly. Injectable semaglutide titrates from 0.25 mg weekly up to 2 mg for Ozempic and 2.4 mg for Wegovy, and injectable tirzepatide runs 2.5 mg to 15 mg weekly as Mounjaro and Zepbound. Oral Rybelsus starts at 3 mg daily and steps to 7 or 14 mg. These are label facts, not personal instructions.

The oral GLP-1 absorption hurdle

Whenever a GLP-1 is formulated as a tablet, timing becomes strict because the drug has to survive the stomach before it can work. That is the core trade-off of skipping the needle. Real-world adherence for any format depends on injection tolerance, the ability to follow administration timing, and lifestyle, which is why format is a personal fit question as much as a clinical one.

PlexusDx does not carry Victoza

PlexusDx does not sell, distribute, or prescribe Victoza or liraglutide. Its Weight Management Protocols include compounded semaglutide and tirzepatide only, with per-protocol pricing published on each product page. Whichever GLP-1 pathway compound you and a provider eventually discuss, the underlying genetic architecture is the same.

Genetics apply across every GLP-1 decision

Variants in FTO, GLP1R, and MC4R shape baseline appetite regulation and energy balance regardless of which compound or format is on the table. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights to describe that context. It does not predict response to liraglutide or any specific medication; it gives you and a provider an informed starting point instead of guesswork.

Where Victoza sits among newer options

Because liraglutide arrived earlier than the weekly agonists, comparisons often frame it as the older, more demanding option, but that framing misses the point. A once-daily schedule suits some people and their routines perfectly well, and format preference is genuinely individual rather than a simple matter of newer being better. What the comparison should really surface is that different GLP-1 pathway compounds carry different dosing rhythms, indications, and administration rules, and matching those to your life is a clinical conversation. Since PlexusDx does not carry Victoza, the practical relevance here is the underlying biology it shares with the compounds PlexusDx does offer, which is exactly where the genetic context discussed above becomes the common thread across every option on the table. Put simply, the question worth asking is less about whether a Victoza pill exists and more about which dosing rhythm, indication, and format actually fit your life, which is a conversation a provider is best placed to have with you.

Frequently Asked Questions

Is there an oral version of Victoza?

Victoza is the liraglutide injection, and the FDA-approved label defines its format. As of April 2026 the only FDA-approved oral GLP-1 receptor agonist is Rybelsus, an oral semaglutide labeled for type 2 diabetes, and there is no FDA-approved oral tirzepatide. Check the prescribing information for any specific product.

How is Victoza dosed compared with newer drugs?

Liraglutide is dosed once daily, which sets it apart from the once-weekly injectable agonists that came later. Weekly options such as semaglutide and tirzepatide reduce injection frequency, while oral semaglutide requires daily fasting administration. A prescriber matches the schedule to your indication and needs.

Does PlexusDx offer Victoza?

No. PlexusDx does not sell, prescribe, or recommend Victoza, liraglutide, or other therapeutic peptides beyond the semaglutide and tirzepatide products in its Weight Management Protocols. This article is educational and describes the format landscape rather than directing you toward any particular medication.

Does the genetic test predict how I'll respond to liraglutide?

No. The Precision Peptide Genetic Test does not predict response to liraglutide or any specific compound or format. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline appetite and energy balance, giving context that applies across every GLP-1 decision.

Keep exploring evidence-based GLP-1 and metabolic resources in the PlexusDx Education Hub.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.